MIT Technology Review July 1, 2025: HHS Deputy Secretary Jim O’Neill wants unproven medical treatments to be very widely available and HHS to focus funding on longevity research so that those who can afford them can live much longer. This could include areas at sea or in states that are not subject to FDA safeguards. What will happen to the millions of Americans who need healthcare for diseases they already have?
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
RFK Jr.’s tough talk on corporate influence isn’t adding up in practice
Environmental Health Network, June 26, 2025: EHN reports that HHS and RFK Jr. claim to stop conflicts of interest, but industry influence and other conflicts remain, as explained by NCHR’s Diana Zuckerman.
Read More »RFK Jr.’s Planned Assault on Corporate Influence Is Clashing With Reality
NOTUS News, June 26, 2025: NOTUS news article gives numerous examples from experts who agree with RFK Jr and Makary criticisms of corporate influence on health, but say HHS plans to reduce conflicts of interest are ineffective and FDA remains overly influenced by industry.
Read More »Biotech pauses trial after second patient death linked to gene therapy
The Washington Post, June 17, 2025; Sarepta restricts Elevidys gene therapy for non-ambulatory Duchenne muscular dystrophy patients after second death. We point out that FDA flexibility “does no favor” to patients who may die from using a questionable treatment. Elevidys costs $3.2 million per patient.
Read More »FDA Approved — And Ineffective
June 5, 2025: New report in The Lever shows that most drugs approved by the FDA do not meet the standards of evidence required by law and we say that the FDA’s standards are the lowest ever
Read More »